Pharmaceutical

Five things for pharma marketers to know: Friday, September 23, 2016

Five things for pharma marketers to know: Friday, September 23, 2016

Anthem and Cigna accuse each other of violating merger terms; Alzheimer's experimental drug fails late-stage study; study calls for new approach to eradicate global epidemics

The Michael J. Fox Foundation uses Facebook to recruit Ashkenazi Jews for Parkinson's study

The Michael J. Fox Foundation uses Facebook to recruit Ashkenazi Jews for Parkinson's study

The organization said it used Facebook to identify participants for a study designed to identify biomarkers associated with Parkinson's disease.

Five things for pharma marketers to know: Tuesday, September 13, 2016

Five things for pharma marketers to know: Tuesday, September 13, 2016

Drugmakers routinely pay ghostwriters to write industry-funded research articles; Horizon to buy Raptor for $800 million; WellDoc partners with J&J

Bolstered by new data, Radius Health focuses on unmet needs in the osteoporosis market

Bolstered by new data, Radius Health focuses on unmet needs in the osteoporosis market

Only one new osteoporosis drug has been approved over the last six years.

Five things for pharma marketers to know: Tuesday, August 16, 2016

Five things for pharma marketers to know: Tuesday, August 16, 2016

OncoGenex's prostate cancer drug fails in clinical trial; Aetna to exit exchanges in 11 states; pregnant women taking acetaminophen have higher risks for their children

Five things for pharma marketers to know: Thursday, August 11, 2016

Five things for pharma marketers to know: Thursday, August 11, 2016

Valeant is under federal investigation; Lilly's breast-cancer drug fails to meet efficacy criteria; new policy opens up medical research of marijuana

Five things for pharma marketers to know: Tuesday, August 9, 2016

Five things for pharma marketers to know: Tuesday, August 9, 2016

Novo Nordisk attributes slow growth to biosimilars, pricing; Dentsu acquires majority stake in Merkle; AZ lung cancer drug fails late-stage trial

Event company acquires AstraZeneca's medical meetings app

Event company acquires AstraZeneca's medical meetings app

The event technology platform plans to integrate a conference note-taking app developed by AstraZeneca and DigitasLBi.

Five things for pharma marketers to know: Thursday, August 4, 2016

Five things for pharma marketers to know: Thursday, August 4, 2016

Researchers test Zika vaccine; Aetna contacts doctors who prescribe high rates of opioids; half of pediatric trials are never published or completed

Five things for pharma marketers to know: Tuesday, July 19, 2016

Five things for pharma marketers to know: Tuesday, July 19, 2016

The FDA declines to approve Novartis biosimilar; GSK partners with Apple's ResearchKit; drugmakers partner with Lyft for clinical trial participants